Evolving Immunotherapy in Myeloma: Insights on Bispecific and Trispecific Antibodies from ASCO 2025

A panelist emphasizes that while trispecific antibodies offer near-perfect response rates and convenient monthly dosing that could improve quality of life, careful assessment of adverse effects like infections and taste disturbances is crucial—especially for lower-risk patients—making patient preference and physician judgment key in determining their optimal use, with high-risk patients with heavily pretreated disease poised to benefit most.

A panelist highlights promising early-phase trial data on trispecific antibodies targeting multiple myeloma antigens and CD3, emphasizing their high response rates, manageable safety profiles, and potential to enhance treatment for heavily relapsed or high-risk patients while noting ongoing questions about optimal patient selection and their role alongside existing bispecific therapies.

A panelist discusses early clinical trial data on combining the B-cell maturation antigen–targeting bispecific antibody linvoseltamab with proteasome inhibitors carfilzomib and bortezomib in relapsed/refractory multiple myeloma, highlighting promising response rates, manageable toxicity profiles, and the potential for these combinations to enhance treatment efficacy pending longer-term follow-up.

A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient experience, while highlighting the importance of timing and sequencing T-cell–targeting therapies to optimize efficacy and immune recovery in multiple myeloma management.

A panelist discusses recent advancements in bispecific antibody therapies for relapsed/refractory multiple myeloma, emphasizing the promising efficacy and improved safety profile of GPRC5D-targeting agents, the importance of patient-specific factors in therapy selection, and the role of prophylactic measures to manage infection risks, supporting personalized treatment strategies.

A panelist discusses the latest advancements presented at ASCO 2025, highlighting talquetamab’s pivotal trial in relapsed/refractory multiple myeloma that demonstrated high response rates and longer durability with biweekly dosing, including in patients previously treated with B-cell maturation antigen–targeted therapies, supporting sequencing and combination strategies to improve outcomes.